| (Values in U.S. Thousands) | Dec, 2019 | Dec, 2018 | Dec, 2017 | Dec, 2016 | Dec, 2015 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | 1,050 | -19,190 | -3,090 | -3,180 | -4,840 |
| Net Income Growth | +105.47% | -521.04% | +2.83% | +34.30% | -77.29% |
Emerald Bioscience Inc (EMBI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Emerald Bioscience Inc. is a biopharmaceutical company. It is focused on the discovery, development, and commercialization of bioengineered cannabinoid-based therapeutics for unmet medical needs. The company's product pipeline consists of NB1111, NB2222 and NB3000 which are in clinical stage. Emerald Bioscience Inc. is based in Long Beach, California.